Published in JCI Insight on December 22, 2016
Twelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients. JCI Insight (2017) 0.75
SOX2 immunity and tissue resident memory in children and young adults with glioma. J Neurooncol (2017) 0.75
Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes. Oncoimmunology (2017) 0.75
Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med (2003) 16.62
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature (2014) 10.49
Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
Comprehensive assessment of T-cell receptor beta-chain diversity in alphabeta T cells. Blood (2009) 7.00
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother (2003) 5.59
viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. Nat Biotechnol (2013) 4.88
NetMHCpan, a method for quantitative predictions of peptide binding to any HLA-A and -B locus protein of known sequence. PLoS One (2007) 3.99
NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics (2008) 3.59
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors. J Clin Invest (2014) 3.54
The developmental pathway for CD103(+)CD8+ tissue-resident memory T cells of skin. Nat Immunol (2013) 3.53
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res (2013) 3.48
Exhaustion of tumor-specific CD8⁺ T cells in metastases from melanoma patients. J Clin Invest (2011) 3.28
Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. Immunity (2012) 3.21
Memory T cell subsets, migration patterns, and tissue residence. Annu Rev Immunol (2012) 3.05
The three human monocyte subsets: implications for health and disease. Immunol Res (2012) 2.08
Tissue-resident memory T cells. Immunity (2014) 2.04
Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell (2014) 1.72
The emerging role of resident memory T cells in protective immunity and inflammatory disease. Nat Med (2015) 1.69
The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol (2012) 1.66
Type II NKT-TFH cells against Gaucher lipids regulate B-cell immunity and inflammation. Blood (2014) 1.63
T cell memory. A local macrophage chemokine network sustains protective tissue-resident memory CD4 T cells. Science (2014) 1.61
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol (2014) 1.58
Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res (2014) 1.54
Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood (2015) 1.53
Human skin is protected by four functionally and phenotypically discrete populations of resident and recirculating memory T cells. Sci Transl Med (2015) 1.38
Phosphoproteomic screen identifies potential therapeutic targets in melanoma. Mol Cancer Res (2011) 1.38
Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer. Clin Cancer Res (2013) 1.30
Resident memory T cells in human health and disease. Sci Transl Med (2015) 1.24
Human CD1c+ dendritic cells drive the differentiation of CD103+ CD8+ mucosal effector T cells via the cytokine TGF-β. Immunity (2013) 1.23
Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. Proc Natl Acad Sci U S A (2015) 1.19
Common clonal origin of central and resident memory T cells following skin immunization. Nat Med (2015) 1.18
CD8+CD103+ tumor-infiltrating lymphocytes are tumor-specific tissue-resident memory T cells and a prognostic factor for survival in lung cancer patients. J Immunol (2015) 1.17
Translational implications of tumor heterogeneity. Clin Cancer Res (2015) 1.12
Characterization of PD-L1 Expression and Associated T-cell Infiltrates in Metastatic Melanoma Samples from Variable Anatomic Sites. Clin Cancer Res (2015) 1.05
Local antigen in nonlymphoid tissue promotes resident memory CD8+ T cell formation during viral infection. J Exp Med (2016) 1.01
Dynamics of the cytotoxic T cell response to a model of acute viral infection. J Virol (2015) 0.96
In situ T cell responses against melanoma comprise high numbers of locally expanded T cell clonotypes. J Immunol (1999) 0.96
Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother (2011) 0.94
The immune landscape of human tumors: Implications for cancer immunotherapy. Oncoimmunology (2014) 0.94
Phylogenetic analyses of melanoma reveal complex patterns of metastatic dissemination. Proc Natl Acad Sci U S A (2015) 0.93
Estimating the ratio of CD4+ to CD8+ T cells using high-throughput sequence data. J Immunol Methods (2013) 0.93
T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int J Cancer (2014) 0.93
Heterogeneity of T-cell clones infiltrating primary malignant melanomas. J Invest Dermatol (2006) 0.89
Tumor- and Neoantigen-Reactive T-cell Receptors Can Be Identified Based on Their Frequency in Fresh Tumor. Cancer Immunol Res (2016) 0.81
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. J Clin Invest (2016) 0.80
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward? Cancer Biol Med (2016) 0.78
ABC transporters and NR4A1 identify a quiescent subset of tissue-resident memory T cells. J Clin Invest (2016) 0.76